Please assess the completion status of the following clinical trial:

Trial Title: Vitamin D3 Supplementation for Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* NYHA Heart Failure Class II or II, stable~* Vitamin D deficiency (32 ng/ml or less)~* No recent medication changes for 3 months~* Females of childbearing age must use effective contraceptive if they are sexually active~Exclusion Criteria:~* Hypercalcemia~* Nephrolithiases~* Sarcoidosis~* Acute cardiac insufficiency~* Pregnancy~* Breastfeeding~* Any clinically unstable medical condition~* Supplements of greater than or equal to 1000 units of vitamin D per day

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vitamin D3 (cholecalciferol) (Type: ACTIVE_COMPARATOR): 10,000 International Units of vitamin D3 will be given daily for 6 months in vitamin D deficient heart failure patients.
- Sugar Pill (Type: PLACEBO_COMPARATOR): Patients will be given an placebo that is identical in appearance to the active comparator. It will be given as 2 gelcaps per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).